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Efficacy and Safety of Ticagrelor Monotherapy 
in Patients Undergoing Percutaneous Coronary 
Intervention: A Meta- Analysis
Georg Gelbenegger1, Christian Schoergenhofer1, Bernd Jilma1, Gloria M. Gager1,2, Al Medina Dizdarevic2, 
Mamas A. Mamas3,4, Biljana Parapid5, Poonam Velagapudi6 and Jolanta M. Siller- Matula2,7,*
Dual antiplatelet therapy (DAPT) and subsequent P2Y12 inhibitor monotherapy, particularly ticagrelor, is an emerging 
treatment strategy in patients undergoing percutaneous coronary intervention (PCI). This meta- analysis was designed 
to investigate whether short- term DAPT followed by ticagrelor monotherapy is associated with a favorable outcome 
as compared with standard DAPT (1– 3 months of DAPT was termed “short- term” DAPT, 6– 12 months DAPT was 
termed “standard” DAPT). The primary outcome was the composite of major adverse cardiovascular events (MACE) 
comprising myocardial infarction, stroke, and cardiovascular death. Secondary outcomes included all- cause mortality 
and net adverse clinical events (NACE; myocardial infarction, stroke, all- cause death, stent thrombosis, and major 
bleeding). The primary safety outcome was major bleeding. Three studies comprising 26,143 patients were included. 
The risk of MACE was similar between the two treatment groups (risk ratio (RR) 0.86, 95% confidence interval (CI), 
0.72– 1.02, P = 0.08, I2 = 22%). Short- term DAPT followed by ticagrelor monotherapy resulted in a 20% relative risk 
reduction of all- cause mortality (RR 0.80, 95% CI, 0.65– 0.98, P = 0.03, I2 = 0%) and an 18% relative risk reduction 
of NACE (RR 0.82, 95% CI, 0.71– 0.94, P = 0.005, I2 = 33%) as compared with standard DAPT. Short- term DAPT 
followed by ticagrelor monotherapy significantly decreased the risk of major bleeding (RR 0.67, 95% CI, 0.49– 0.92, 
P = 0.01, I2 = 65%). In patients with acute coronary syndrome, short- term DAPT followed by ticagrelor monotherapy 
resulted in an unchanged ischemic risk but a significantly lower bleeding risk compared with standard DAPT. Short- 
term DAPT followed by ticagrelor monotherapy compared with standard DAPT resulted in a favorable safety and 
efficacy profile. Direct comparisons of aspirin vs. ticagrelor monotherapy following PCI are needed.
Dual antiplatelet therapy (DAPT), defined as a combination of as-
pirin plus a P2Y12 inhibitor, has become the cornerstone treatment 
in patients with acute coronary syndrome (ACS) or undergoing 
planned percutaneous coronary intervention (PCI).1,2 For patients 
with stable coronary artery disease undergoing PCI and no high 
bleeding risk, current guidelines, from both the European Society 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Dual antiplatelet therapy (DAPT) is effective in preventing 
thromboembolic complications following percutaneous coro-
nary intervention (PCI) but is associated with an increased risk 
of bleeding. P2Y12 inhibitor monotherapy, as opposed to aspirin 
monotherapy, has emerged as an up- and- coming treatment regi-
men following DAPT.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study sought to evaluate the efficacy and safety of tica-
grelor monotherapy following PCI.
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 Short- term DAPT (1– 3 months) followed by ticagrelor mon-
otherapy was associated with less all- cause mortality, net ad-
verse clinical events, and major bleeding but an unchanged risk 
of ischemic events compared with standard DAPT (12 months).
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Short- term DAPT followed by ticagrelor monotherapy is 
safe and effective and may present an attractive treatment regi-
men in patients with a high bleeding risk.
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of Cardiology (ESC) and the American College of Cardiology 
(ACC)/American Heart Association (AHA), recommend DAPT 
with clopidogrel for the duration of 6 months.1,2 For patients with 
ACS that are being treated with PCI, both guidelines suggest 
DAPT for a period of 12 months, with a class IIb recommenda-
tion to continue DAPT for an extended period over 1 year.
However, due to the increased risk of bleeding complications 
accompanying DAPT and associated compliance/adherence 
problems, shortening of DAPT or switching to single antiplate-
let therapy have become options in patients undergoing PCI.3 In 
contrast to primary prevention,4 aspirin’s efficacy in secondary 
prevention of cardiovascular disease is well- established,5 but its 
status as cornerstone treatment in antithrombotic therapy is being 
challenged due to the (i) increased bleeding events (especially with 
concomitant P2Y12 inhibitor use or anticoagulation and in the 
elderly population),6 (ii) reduction of cardiovascular events by 
other cardiovascular drug classes, and (iii) and the introduction of 
other potent antiplatelet agents.7 Furthermore, the development 
of newer- technology drug- eluting stents with ultra- thin struts and 
bioresorbable polymers warrants stratified approaches toward du-
ration of DAPT.8– 12
These changes have prompted studies investigating P2Y12 inhib-
itor monotherapy with ticagrelor. This meta- analysis summarizes 
studies on P2Y12 inhibitor monotherapy with ticagrelor after PCI 
and discusses their clinical implications.
METHODS
Data sources
Our trial was registered with PROSPERO under the ID 
CRD42020211516. We conducted a systematic search in the PubMed, 
Cochrane, Embase, and Web of Science from database inception through 
the final search date of June 30, 2020. We used the subsequent predefined 
search terms: ticagrelor monotherapy AND dual antiplatelet therapy 
AND duration AND bleeding. No language, publication date, or pub-
lication status restrictions were applied. References of retrieved articles 
and prior meta- analyses were checked for additional studies.
Trial eligibility and data extraction
This study was conducted in accordance with Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses (PRISMA) guide-
lines (Table  S1) and performed according to established methods, 
as described previously.13,14 Only full- text articles were included. 
Trials that (i) compared any different DAPT durations after PCI and 
used ticagrelor monotherapy, (ii) were randomized controlled trials, 
and (iii) reported on at least one of the outcomes of interest (major 
adverse cardiovascular events (MACE), myocardial infarction (MI), 
stroke, stent thrombosis (ST), all- cause death, cardiovascular death, 
and major bleeding) were included. Eligible reports were assessed 
for methodological quality using the Cochrane Risk of Bias Tool 
(Table  S2). Studies were excluded if one could determine, from the 
title, or abstract, or both, that the study was not suitable for inclu-
sion. Full text of the study was obtained and evaluated if an article 
could not be excluded with certainty. Two reviewers (authors G.G. and 
J.M.S.M.) independently and in duplicate applied the selection crite-
ria. Any discrepancy was resolved by author consensus.
Outcomes and subgroup analysis
The primary efficacy outcome was the composite of MACE (the compos-
ite of MI, stroke, and cardiovascular death). The secondary efficacy out-
comes included all- cause death, cardiovascular death, MI, ST, and stroke. 
We also calculated the composite of net adverse clinical events (NACE; 
composite of MI, stroke, all- cause death, ST, and major bleeding). Major 
bleeding was defined as the primary safety outcome. Two different bleed-
ing definitions, Thrombolysis in Myocardial Infarction (TIMI)15 and 
Bleeding Academic Research Consortium (BARC),16 were used in the 
trials included in this meta- analysis.
All outcomes were analyzed by an intention- to- treat analysis. We per-
formed subgroup analyses for the primary efficacy outcome and the pri-
mary safety outcome, including only patients presenting with ACS and 
patients undergoing complex or noncomplex PCI. The definitions of 
complex PCI differed in the GLOBAL LEADERS and the TWILIGHT 
trial. Details about the differences between the definitions of complex 
PCI are shown in Table S3.
Due to the heterogenous definitions of MACE and NACE used, we 
performed sensitivity analyses using the MACE/NACE definitions from 
each individual study.
Data synthesis and statistical analysis
DAPT durations were categorized into short- term DAPT (1– 3 months) 
and standard DAPT (6– 12 months). Variables were reported as number 
or percentages, as appropriate. Risk ratios (RRs) were computed from 
individual studies and pooled according to the inverse variance random 
effect method with 95% confidence intervals (CIs) using Review Manager 
(version 5.4; The Cochrane Collaboration, 2020). Unadjusted P values 
were reported throughout, with hypothesis testing set at the 2- tailed sig-
nificance level of 0.05. We assessed studies for clinical and statistical het-
erogeneity. To assess statistical heterogeneity, we calculated the I2 index 
and a P value. Percentages < 25% (I2 = 25), 25– 50% (I2 = 50), and 50– 75% 
(I2 = 75) correlate to low, medium, and high heterogeneities, respectively.17 
Due to the high clinical heterogeneity, we used the random- effect model.
RESULTS
Our search yielded 74 references. The flow diagram depicting our 
search algorithm is shown in Figure S1. Three studies, including 
a total of 26,143 patients, met our inclusion criteria.18– 20 The 
TWILIGHT19 and the TICO trials18 both had a follow- up of 
12  months. The GLOBAL LEADERS trial20 provided a 2- year 
follow- up, yet for consistency of data, we chose to include data from 
the 1- year follow- up. Further, the GLOBAL LEADERS trial20 did 
not report on the outcome of cardiovascular mortality, so all- cause 
mortality was used for the composite end point MACE.
Specific data for the ACS subgroup of the GLOBAL 
LEADERS was taken from a post hoc analysis.21 In the same 
manner, data for the complex/noncomplex PCI subgroups were 
taken from post hoc analyses from the GLOBAL LEADERS22 
and the TWILIGHT trials.23 Data from the GLOBAL 
LEADERS trial for the sensitivity analysis of NACE was taken 
from another post hoc analysis.24
All studies18– 20 exclusively included patients who underwent 
PCI with placement of a drug- eluting stent. The TWILIGHT trial 
included patients with high ischemic or bleeding risk but excluded 
patients presenting with ST- elevation MI.19 The TICO trial only 
included patients presenting with ACS but excluded patients with 
an increased risk of bleeding.18 Detailed information on the stud-
ies included can be found in Table 1 and Table S4.
Primary efficacy outcome: Major adverse cardiovascular 
events
Short- term DAPT followed by ticagrelor monotherapy was as-
sociated with a trend toward a decreased risk of MACE (RR 
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0.86, 95% CI, 0.72– 1.02, P = 0.08, I2 = 22%; Figure 1a) com-
pared with standard DAPT. The absolute risk reduction, num-
ber needed to treat, and number of events reduced per 1,000 
patients treated of the major outcomes of this study are shown 
in Table 2.
Secondary efficacy outcomes
Short- term DAPT followed by ticagrelor monotherapy resulted 
in a significant 18% relative risk reduction of the composite of 
NACE as compared with standard DAPT (RR 0.82, 95% CI, 
0.71– 0.94, P = 0.005, I2 = 33%; Figure 1b), resulting in a favor-
able net clinical benefit.
Short- term DAPT followed by ticagrelor monotherapy was as-
sociated with a significant 20% relative risk reduction of all- cause 
death (RR 0.80, 95% CI, 0.65– 0.98, P = 0.03, I2 = 0%; Figure 1c), 
as compared with standard DAPT.
Two trials, the TWILIGHT19 and the TICO trials,18 reported 
on the outcome of cardiovascular death. Short- term DAPT was 
associated with a similar risk of cardiovascular death as compared 
with standard DAPT (RR 0.68, 95% CI, 0.44– 1.05, P  =  0.08, 
I2 = 0%; Figure S2a).
There were no statistically significant differences between 
short- term DAPT followed by ticagrelor monotherapy and stan-
dard DAPT regarding the relative risk of MI (RR 1.06, 95% CI, 
0.88– 1.27, P = 0.57, I2 = 11%; Figure S2b), ST (RR 1.14, 95% CI, 
0.80– 1.62, P = 0.48, I2 = 4%; Figure S2c), stroke (RR 1.13, 95% 
CI, 0.73– 1.76, P = 0.58, I2 = 27%; Figure S2d) or target vessel 
revascularization (RR 0.87, 95% CI, 0.75– 1.02, P = 0.10, I2 = 0%; 
Figure S2e).
Primary safety outcome: Major bleeding
One study18 reported on the major bleeding outcome according to 
the TIMI bleeding classification and all three studies18– 20 accord-
ing to the BARC bleeding classification.
Short- term DAPT followed by ticagrelor monotherapy sig-
nificantly decreased the risk of major bleeding (according to the 
BARC bleeding classification) compared with standard DAPT 
(RR 0.67, 95% CI, 0.49– 0.92, P = 0.01, I2 = 65%; Figure 2).
Subgroup analysis: Acute coronary syndrome
All three studies provided data on the ACS subgroup.18,19,21
In patients presenting with ACS, standard DAPT was associ-
ated with an unchanged risk of MACE compared with short- term 
DAPT followed by ticagrelor monotherapy (RR 0.91, 95% CI, 
0.74– 1.12, P = 0.38, I2 = 15%; Figure 3a).
Patients with ACS receiving short- term DAPT followed by tica-
grelor monotherapy had significantly lower risk of major bleeding 
compared with patients with ACS receiving standard DAPT (RR 
0.50, 95% CI, 0.40– 0.61, P < 0.00001, I2 = 0%; Figure 3b).
Subgroup analysis: Complex/noncomplex PCI
Post hoc analyses from two trials, GLOBAL LEADERS22 and 
TWILIGHT,23 provided data on patients undergoing complex or 
noncomplex PCI.
In patients undergoing complex PCI, short- term DAPT fol-
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lower risk of MACE compared with standard DAPT (RR 0.72, 
95% CI, 0.56– 0.93, P = 0.01, I2 = 0%; Figure 3c). There was no 
difference between treatment groups in patients undergoing non-
complex PCI (RR 0.98, 95% CI, 0.78– 1.23, P = 0.84, I2 = 33%; 
Figure 3c).
In patients undergoing complex or noncomplex PCI, there was 
no significant difference between treatment groups, however, both 
subgroups showed a trend toward a reduction of major bleeding in 
the short- term DAPT followed by ticagrelor monotherapy group 
(RR 0.62, 95% CI, 0.30– 1.30, P = 0.21, I2 = 72%; Figure 3d and 
RR 0.74, 95% CI, 0.48– 1.14, P  =  0.17, I2  =  54%, respectively; 
Figure 3d).
Sensitivity analysis: MACE (according to the individual 
studies’ definition)
When the individual studies’ definition of MACE was used, 
short- term DAPT followed by ticagrelor monotherapy signifi-
cantly decreased the risk of MACE (RR 0.86, 95% CI, 0.74– 
0.99, P = 0.04, I2 = 10%; Figure S3a) compared with standard 
DAPT.
Figure 1 Forest plot showing the risk ratio of (a) major adverse cardiovascular events (MACE), (b) net adverse clinical events (NACE) and (c) 
all- cause mortality according to the two treatment regimens: short- term dual antiplatelet therapy (DAPT) followed by ticagrelor monotherapy vs. 
standard DAPT. CI, confidence interval.
MACE




Table 2 The RRR, ARR, the NNT, the number of events reduced per 1,000 patients treated, and the P value of the major 
outcomes of this study
RRR, % ARR, % NNT
No. of events reduced per 1,000 
treated patients P value
MACE 14 0.4 250 4 0.08
NACE 18 0.9 111 9 0.005
All- cause mortality 20 0.3 333 3 0.03
Major bleeding 33 0.6 167 6 0.01
ARR, absolute risk reduction; MACE, major adverse cardiovascular event; NACE, net adverse clinical event; NNT, number needed to treat; RRR, relative risk 
reduction.
Bold indicates the values P < 0.05 are statistically significant.
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Sensitivity analysis: NACE (according to the individual 
studies’ definition)
The GLOBAL LEADERS trial24 and the TICO trial18 reported 
on the incidence of NACE. When the individual studies’ defi-
nition of NACE was used, there was no statistically significant 
difference between short- term DAPT followed by ticagrelor 
monotherapy and standard DAPT regarding the relative risk 
of NACE (RR 0.81, 95% CI, 0.59– 1.11, P  =  0.19, I2  =  73%; 
Figure S3b).
DISCUSSION
This systematic review and meta- analysis comprise three trials 
(>  26,000 patients) investigating the novel concept of ticagrelor 
monotherapy in patients undergoing PCI following a short- term 
treatment with DAPT. All included studies compared short- term 
DAPT (1– 3  months) followed by P2Y12 inhibitor monotherapy 
with ticagrelor to standard DAPT (12 months).
Our meta- analysis shows that short- term DAPT followed by 
ticagrelor monotherapy is safe and effective. In particular, we 
demonstrate that, compared with standard DAPT, short- term 
DAPT followed by ticagrelor monotherapy (i) is associated 
with a trend towards a reduced risk of MACE, (ii) significantly 
decreases all- cause mortality and the risk of NACE and major 
bleeding, and (iii) results in an unchanged risk of cardiovascular 
death, MI, ST, and stroke. See Figure 4 for the summary of key 
outcomes.
The balance between ischemic and bleeding risks determines 
the overall benefit of antithrombotic treatments. Across all three 
included studies,18– 20 short- term DAPT followed by ticagrelor 
monotherapy resulted in an unchanged risk of MACE compared 
with standard DAPT. Although the TICO18 and TWILIGHT 
trials19 found significant increases of major bleeding events with 
standard DAPT, the GLOBAL LEADERS trial20 could not de-
tect a significant difference between the treatment groups. This is 
rather unexpected, as the GLOBAL LEADERS trial20 compared 
the shortest DAPT duration (1 month) to standard DAPT— the 
other two trials18,19 both compared 3- month DAPT to standard 
12- month DAPT— which may have led to the assumption that 
it would show the greatest relative risk reduction of major bleed-
ing. In contrast, the TWILIGHT trial19 included both high- risk 
bleeding and ischemic patients and therefore expectedly demon-
strated a significantly increased risk of major bleeding events in 
patients with standard DAPT. The TICO trial18 excluded patients 
at increased risk of bleeding, yet still showed a significant decrease 
of major bleeding events in the short- term DAPT followed by tica-
grelor monotherapy group.
Interestingly, short- term DAPT followed by ticagrelor mono-
therapy significantly decreased all- cause mortality compared with 
standard DAPT, which may be due to the accompanying decreased 
risk of major bleeding. Further studies investigating the particular 
concept of P2Y12 inhibitor/ticagrelor monotherapy are needed 
to underscore and confirm this result. Indeed, the reduction of 
major bleeding following PCI is an important clinical aim, due to 
its strong association with mortality.25 All three trials18– 20 in this 
analysis compared short- term DAPT followed by ticagrelor mono-
therapy to standard DAPT. Conceivably, it is easier to demonstrate 
less bleeding with a single antiplatelet therapy regimen than with a 
DAPT regimen, and our meta- analysis confirmed the significant 
reduction of major bleeding events with short- term DAPT fol-
lowed by ticagrelor monotherapy compared with standard DAPT.
In contrast, short- term DAPT followed by ticagrelor mono-
therapy was associated with an unchanged relative risk of MACE 
compared with standard DAPT, even showing a trend toward 
fewer events in the ticagrelor monotherapy treatment group, which 
makes it an attractive and feasible treatment option in the future. 
This is further substantiated by the significant results in favor of 
short- term DAPT followed by ticagrelor monotherapy in our net 
clinical benefit analysis (Figure 1b).
Compared with ticagrelor monotherapy, aspirin monotherapy 
may have similar efficacy in reducing bleeding events, with poten-
tially no increased risk of MACE. Each of the three clinical tri-
als fall short of a duly needed third study arm, investigating the 
effects of short- term DAPT followed by aspirin monotherapy. 
The head- to- head comparison of short- term DAPT followed by 
aspirin vs. P2Y12 inhibitor (ticagrelor in particular) monother-
apy is, however, missing. Given the relatively inexpensive costs 
of aspirin compared with ticagrelor and increased risk of discon-
tinuation due to side effects, such as dyspnea, a three- way study 
design would be of major interest. Two studies, the RESET26 and 
the OPTIMIZE27 trials, have investigated the concept of short- 
term DAPT (1– 3  months) followed by aspirin monotherapy vs. 
standard DAPT (6– 12 months). Both studies used zotarolimus- 
eluting stents only and found no change in ischemic and bleeding 
risk between groups.
Figure 2 Forest plot showing the risk ratio of major bleeding (Bleeding Academic Research Consortium (BARC) 3– 5) according to the bleeding 
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Results from a meta- analysis comparing monotherapy with a 
P2Y12 inhibitor vs. aspirin for secondary prevention of cardiovas-
cular disease show that P2Y12 inhibitor monotherapy was associ-
ated with a relative risk reduction of myocardial infarction but an 
unchanged risk of stroke, all- cause death, cardiovascular death, and 
major bleeding.28 The benefit of P2Y12 inhibitor monotherapy is, 
however, questionable due to the high number needed to treat to 
prevent myocardial infarction and the lack of effect on mortality.
Figure 3 Subgroup analyses. Forest plot showing the risk ratio of (a) major adverse cardiovascular event (MACE) in patients presenting 
with acute coronary syndrome (ACS), (b) major bleeding in patients presenting with ACS, and (c) MACE in patients undergoing complex or 
noncomplex percutaneous coronary intervention (PCI), and (d) major bleeding in patients undergoing complex or noncomplex PCI according to 
the two treatment regimens: short- term dual antiplatelet therapy (DAPT) followed by ticagrelor monotherapy vs. standard DAPT.
MACE in ACS
MAJOR BLEEDING in ACS




(d) MAJOR BLEEDING in Complex/Non-complex PCI
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Clinical implications
The available evidence shows that ticagrelor monotherapy might 
be effective and safe after an initial phase of DAPT. This might 
be of particular interest in patients with high bleeding risk. 
Importantly, a comparison of aspirin vs. ticagrelor monotherapy 
would be of great interest. Whether patients with high bleeding 
risk might benefit in terms of the net outcome from short- term 
DAPT with subsequent P2Y12 inhibitor monotherapy com-
pared with standard DAPT, is now additionally investigated in 
upcoming trials (A- CLOSE trial: NCT03947229 and SMART- 
CHOICEII trial: NCT03119012). For bleeding risk assessment, 
the PRECISE- DAPT score may be used.29 The management 
of patients with both high ischemic and bleeding risk remains 
challenging and may necessitate an individualized antiplatelet 
approach.
Our meta- analysis further supports the use of short- term 
DAPT followed by ticagrelor monotherapy compared with stan-
dard DAPT in patients presenting with ACS, as it was associated 
with an unchanged ischemic risk and a significant reduction of 
bleeding events. Current ESC guidelines on the management of 
patients presenting without persistent ST- segment elevation MI 
have already incorporated the possibility of an aspirin- free treat-
ment strategy, depending on the balance between the ischemic 
and bleeding risk (class IIa, level A recommendation).30 This 
recommendation may be extended to patients presenting with 
ST- segment MI and patients with chronic coronary syndrome 
in the future.
The use of ticagrelor monotherapy following short- term DAPT 
may also be warranted in patients undergoing complex PCI, as it 
was associated with a lower ischemic and an unchanged bleeding 
risk compared with standard DAPT.
Limitations
Our meta- analysis has several limitations. First, its limited sam-
ple size, including only three trials and comprising a total of 
just 26,143 patients, precludes universal statements. Second, 
the patient population included was heterogenous and in-
cluded patients at different ischemic and bleeding risks. One 
study only included patients presenting with ACS.18 Third, 
this meta- analysis lacks patient- level data, which precludes the 
evaluation of relevant subgroups and renders the performance 
of an accurate time- to- event analysis impossible. Fourth, for 
the composite end point MACE in the GLOBAL LEADERS 
trial, all- cause mortality had to be used instead of cardiovascu-
lar mortality due to the unavailability of data. Fifth, this study 
assigns equal footing to the various outcomes of NACE despite 
differently weighted risks in real life.
CONCLUSION
Compared with standard DAPT, short- term DAPT followed by 
P2Y12 inhibitor monotherapy with ticagrelor resulted in an un-
changed ischemic risk but decreased all- cause mortality, the rel-
ative risk of NACE, and major bleeding. Direct comparisons of 
aspirin vs. P2Y12 inhibitor monotherapy (in particular ticagrelor) 
after coronary stent implantation are needed.
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